Popular Searches:

Your Previous Searches:

Recently Visited Pages:

Home
Equities
Equities
View All Equities
Equities by Sector

Consumer

Energy & Resources

Financials

Healthcare

Industrials

Investment Companies

Metals & Mining

Real Estate

TMT

Chosa

MCap

SEK57m

Last close

SEK0.80

▲ 0.20 (33.33%)

Vection Technologies

MCap

AUD47m

Last close

AUD0.04

▲ 0.00 (12.90%)

Metro Bank

MCap

GBP684m

Last close

GBP1.02

▲ 7.90 (8.43%)
Sectors
Sectors
Thematics
Thematics
View All Thematics

Latest
Audiovisual
Audiovisual
View All Audiovisual

Latest

Events
About Edison
About Edison
About Edison

Careers

“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”

Financial Director
Equity Research
Investor Relations
Contact us

CASI Pharmaceuticals – executive interview

CASI Pharmaceuticals – executive interview

CASI Pharmaceuticals — 1 video in collection

More on this equity

CASI Pharmaceuticals is focused on building a portfolio of drugs which it intends to produce for Chinese and worldwide markets. Its products are focused on the hematology and oncology space, including its first product, Evomela, launched in China in 2019. The company is also developing an anti-CD19 CAR-T therapy, CNCT19, and the anti-CD38 drug CID-103, among others. The goal is to seek approval through new pathways that have opened in the quickly changing Chinese regulatory environment.

< Previous

Next >

You may also be interested in these:

Healthcare

22.11.24

Recce Pharmaceuticals – executive interview

Healthcare

29.10.24

Making the ordinary, extraordinary: Next generation T cell receptors for precision immunotherapies

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free